Cell and Gene Therapy Insights Volume 5 Issue 8

CELL AND GENE THERAPY INSIGHTS

Volume 5 Issue 8

Cell and Gene Therapy Insights Volume 5 Issue 8

Download PDF

Featuring

Issue Spotlight: Market & Patient Access
Other articles

Market & Patient Access

Lee Buckler

Guest Editor:

Lee Buckler, President & Chief Executive Officer at RepliCel Life Sciences

Perspective

Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations

Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations

T Qiu, E Hanna, M Dabbous et al.

4 September 2019

Breakthrough therapies, breakthrough economics in the era of cure

Breakthrough therapies, breakthrough economics in the era of cure

S Farnia, L Mostovoy, C Redding Flamm et al.

4 September 2019

Genetic-based therapies: looking ahead to ensuring access to a cure for cystic fibrosis

Genetic-based therapies: looking ahead to ensuring access to a cure for cystic fibrosis

Lisa B Feng, Jacqueline V Erdo, Mary B Dwight

4 September 2019

The diversity in regenerative medicines regulations in Europe, USA and Japan

The diversity in regenerative medicines regulations in Europe, USA and Japan

T Qiu, M Dabbous, L Chachoua et al.

4 September 2019

Interview

Future trends in commercial cell and gene therapy: the investor’s perspective

Future trends in commercial cell and gene therapy: the investor’s perspective

Gregory Bonfiglio

4 September 2019

Value demonstration and advanced therapies: the ARM perspective

Value demonstration and advanced therapies: the ARM perspective

Janet Lynch Lambert

4 September 2019

Staying ahead of the curve: NICE’s approach to HTA of novel fields of biotech innovation

Staying ahead of the curve: NICE’s approach to HTA of novel fields of biotech innovation

4 September 2019

Market access in the era of personalized cell & gene therapy

Market access in the era of personalized cell & gene therapy

Edward Abrahams

4 September 2019

An outcomes-based, innovative reimbursement mechanism for curative medicines

An outcomes-based, innovative reimbursement mechanism for curative medicines

3 September 2019

articles

Interview

How commercial biopharma experience is shaping cell & gene therapy facility design

How commercial biopharma experience is shaping cell & gene therapy facility design

Niranjan Kulkarni, PhD, Allan Bream, Grace Linton, RA, AIA, LEED AP BD+C

Commercial Insights

Cell & Gene Therapy Commercial Insight – July 2019

Cell & Gene Therapy Commercial Insight – July 2019

Mark Curtis, Richard Philipson